Related coverage linked through entity extraction aliases.
Feb 16, 2026
Natco Pharma received CDSCO approval to manufacture and launch generic semaglutide injection in India next month for type 2 diabetes treatment, sending shares up over 11% on Monday.
Feb 13, 2026
Natco Pharma has received approval from India's CDSCO to manufacture and market generic semaglutide injection, with a March 2026 launch planned. The approval comes amid patent litigation and intense competition in India's rapidly expanding diabetes and obesity drug market.
Dec 19, 2025
Eli Lilly has built $1.5 billion in pre-launch inventory of oral weight loss drug orforglipron ahead of an April 2026 FDA decision, while Phase 3 data showed the drug maintained weight loss after switching from injectables.
